Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2018 Dec 10. pii: S0140-6736(18)33003-4. doi: 10.1016/S0140-6736(18)33003-4. [Epub ahead of print]

PMID:
30545780
2.

MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Xie Z, Chooi JY, Toh SHM, Yang D, Basri NB, Ho YS, Chng WJ.

Leukemia. 2018 Nov 23. doi: 10.1038/s41375-018-0300-0. [Epub ahead of print]

PMID:
30470837
3.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

4.

Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.

Chong PSY, Zhou J, Chooi JY, Chan ZL, Toh SHM, Tan TZ, Wee S, Gunaratne J, Zeng Q, Chng WJ.

Oncogene. 2018 Oct 10. doi: 10.1038/s41388-018-0526-3. [Epub ahead of print]

PMID:
30305722
5.

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.

Zhou J, Chng WJ.

World J Clin Oncol. 2018 Sep 14;9(5):90-97. doi: 10.5306/wjco.v9.i5.90. Review.

6.

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.

Chu-Farseeva YY, Mustafa N, Poulsen A, Tan EC, Yen JJY, Chng WJ, Dymock BW.

Eur J Med Chem. 2018 Oct 5;158:593-619. doi: 10.1016/j.ejmech.2018.09.024. Epub 2018 Sep 11.

PMID:
30243158
7.

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.

Arora L, Kumar AP, Arfuso F, Chng WJ, Sethi G.

Cancers (Basel). 2018 Sep 13;10(9). pii: E327. doi: 10.3390/cancers10090327. Review.

8.

LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).

Hee YT, Yan J, Nizetic D, Chng WJ.

Oncotarget. 2018 Aug 7;9(61):31832-31841. doi: 10.18632/oncotarget.25835. eCollection 2018 Aug 7.

9.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL.

Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.

PMID:
30093402
10.

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaan0941. doi: 10.1126/scitranslmed.aan0941.

PMID:
30089632
11.

ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Zhou J, Ng Y, Chng WJ.

Cell Mol Life Sci. 2018 Nov;75(21):3931-3941. doi: 10.1007/s00018-018-2895-8. Epub 2018 Jul 31. Review.

PMID:
30066088
12.

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ.

Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30.

PMID:
30061158
13.

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, Pang WL, Kizhakeyil A, Wijaya GC, Huang DC, Nagarajan S, Chia BK, Cheah D, Liu YH, Zhang F, Rao HL, Tang T, Wong EK, Bei JX, Iqbal J, Grigoropoulos NF, Ng SB, Chng WJ, Teh BT, Tan SY, Verma NK, Fan H, Lim ST, Ong CK.

Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.

14.

BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.

Zhou Y, Zhou J, Lu X, Tan TZ, Chng WJ.

BMC Cancer. 2018 Jul 11;18(1):731. doi: 10.1186/s12885-018-4661-6.

15.

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.

de Mel S, Soon GS, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, Ng SB.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1931. doi: 10.3390/ijms19071931. Review.

16.

Potential Clinical Application of Genomics in Multiple Myeloma.

Soekojo CY, de Mel S, Ooi M, Yan B, Chng WJ.

Int J Mol Sci. 2018 Jun 10;19(6). pii: E1721. doi: 10.3390/ijms19061721. Review.

17.

Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation.

Ng IK, Lee J, Ng C, Kosmo B, Chiu L, Seah E, Mok MMH, Tan K, Osato M, Chng WJ, Yan B, Tan LK.

Biomark Res. 2018 May 11;6:16. doi: 10.1186/s40364-018-0130-2. eCollection 2018.

18.

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.

Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, Siveen KS, Sethi G, Chng WJ, Kumar AP.

Front Pharmacol. 2018 May 3;9:365. doi: 10.3389/fphar.2018.00365. eCollection 2018.

19.

Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.

Khoo AL, Zhao YJ, Teng M, Ying D, Jin J, Chee YL, Poon LM, Lim SE, Koh LP, Chng WJ, Lim BP, Hsu LY, Chai LYA.

Int J Antimicrob Agents. 2018 Sep;52(3):350-357. doi: 10.1016/j.ijantimicag.2018.04.017. Epub 2018 May 9.

PMID:
29751120
20.

Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.

JCI Insight. 2018 May 3;3(9). pii: 98561. doi: 10.1172/jci.insight.98561. [Epub ahead of print]

21.

NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B.

Zhou J, Chooi JY, Ching YQ, Quah JY, Toh SH, Ng Y, Tan TZ, Chng WJ.

World J Stem Cells. 2018 Apr 26;10(4):34-42. doi: 10.4252/wjsc.v10.i4.34.

22.

Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma.

de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, Donato LKS, Halim NAA, Mah J, Lim K, Poon LM, Tan B, Yelly, Lim HL, Koh LP, Tai BC, Chen Z, Chng WJ, Gopalakrishnan SK, Tan LK.

Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225-232. doi: 10.1016/j.hemonc.2018.04.001. Epub 2018 Apr 23.

23.

A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase.

Zhou J, Toh SH, Chan ZL, Quah JY, Chooi JY, Tan TZ, Chong PSY, Zeng Q, Chng WJ.

J Hematol Oncol. 2018 Mar 7;11(1):36. doi: 10.1186/s13045-018-0581-9.

24.

Paraprotein interference in the diagnosis of hepatitis C infection.

Ong L, Abid MB, Yip A, Choong C, Chng WJ, de Mel S.

Clin Chem Lab Med. 2018 Jul 26;56(8):e194-e196. doi: 10.1515/cclm-2017-1148. No abstract available.

PMID:
29494337
25.

Identification of novel fusion transcripts in multiple myeloma.

Lin M, Lee PL, Chiu L, Chua C, Ban KHK, Lin AHF, Chan ZL, Chung TH, Yan B, Chng WJ.

J Clin Pathol. 2018 Aug;71(8):708-712. doi: 10.1136/jclinpath-2017-204961. Epub 2018 Feb 16.

PMID:
29453220
26.

Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.

Xiao L, Chen C, Li Z, Zhu S, Tay JC, Zhang X, Zha S, Zeng J, Tan WK, Liu X, Chng WJ, Wang S.

Cytotherapy. 2018 Mar;20(3):420-435. doi: 10.1016/j.jcyt.2017.12.014. Epub 2018 Feb 3.

PMID:
29402645
27.

Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction.

Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, Yuen YC, Wong HC, Lin A, Poon LM, Koh LP, Chng WJ, Tan LK.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174-179. doi: 10.1016/j.clml.2017.12.010. Epub 2018 Jan 5.

PMID:
29398647
28.

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.

Tan D, Lee JH, Chen W, Shimizu K, Hou J, Suzuki K, Nawarawong W, Huang SY, Sang Chim C, Kim K, Kumar L, Malhotra P, Chng WJ, Durie B; Asian Myeloma Network.

Leuk Lymphoma. 2018 Oct;59(10):2305-2317. doi: 10.1080/10428194.2018.1427858. Epub 2018 Feb 2.

PMID:
29390932
29.

VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.

Mustafa N, Ting Lee JX, Adina Nee HF, Bi C, Chung TH, Hart S, Chng WJ.

Oncotarget. 2017 Oct 20;8(60):101847-101864. doi: 10.18632/oncotarget.21988. eCollection 2017 Nov 24.

30.

Tumor-derived exosomes in colorectal cancer progression and their clinical applications.

Zhou J, Li XL, Chen ZR, Chng WJ.

Oncotarget. 2017 Aug 10;8(59):100781-100790. doi: 10.18632/oncotarget.20117. eCollection 2017 Nov 21. Review.

31.

Epigenetic silencing of EVL/miR-342 in multiple myeloma.

Li Z, Wong KY, Chan GC, Chng WJ, Chim CS.

Transl Res. 2018 Feb;192:46-53. doi: 10.1016/j.trsl.2017.11.005. Epub 2017 Nov 23.

PMID:
29242101
32.

CEBPA mutational analysis in acute myeloid leukaemia by a laboratory-developed next-generation sequencing assay.

Ng CWS, Kosmo B, Lee PL, Lee CK, Guo J, Chen Z, Chiu L, Lee HK, Ho S, Zhou J, Lin M, Tan KML, Ban KHK, Tan TW, Chng WJ, Yan B.

J Clin Pathol. 2018 Jun;71(6):522-531. doi: 10.1136/jclinpath-2017-204825. Epub 2017 Nov 27.

PMID:
29180507
33.

Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes.

Ng SB, Chung TH, Kato S, Nakamura S, Takahashi E, Ko YH, Khoury JD, Yin CC, Soong R, Jeyasekharan AD, Hoppe MM, Selvarajan V, Tan SY, Lim ST, Ong CK, Nairismägi ML, Maheshwari P, Choo SN, Fan S, Lee CK, Chuang SS, Chng WJ.

Haematologica. 2018 Feb;103(2):278-287. doi: 10.3324/haematol.2017.180430. Epub 2017 Nov 2.

34.

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.

Goh JG, Ravikumar S, Win MS, Cao Q, Tan AL, Lim JHJ, Leong W, Herbrecht R, Troke PF, Kullberg BJ, Netea MG, Chng WJ, Dan YY, Chai LYA.

Cell Microbiol. 2018 Mar;20(3). doi: 10.1111/cmi.12798. Epub 2017 Dec 20.

PMID:
29088499
35.
36.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Avet-Loiseau H, Bahlis NJ, Chng WJ, Masszi T, Viterbo L, Pour L, Ganly P, Palumbo A, Cavo M, Langer C, Pluta A, Nagler A, Kumar S, Ben-Yehuda D, Rajkumar SV, San-Miguel J, Berg D, Lin J, van de Velde H, Esseltine DL, di Bacco A, Moreau P, Richardson PG.

Blood. 2017 Dec 14;130(24):2610-2618. doi: 10.1182/blood-2017-06-791228. Epub 2017 Oct 20.

37.

Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.

Yao L, Mustafa N, Tan EC, Poulsen A, Singh P, Duong-Thi MD, Lee JXT, Ramanujulu PM, Chng WJ, Yen JJY, Ohlson S, Dymock BW.

J Med Chem. 2017 Oct 26;60(20):8336-8357. doi: 10.1021/acs.jmedchem.7b00678. Epub 2017 Oct 10.

PMID:
28953386
38.

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA.

Leuk Lymphoma. 2018 Jun;59(6):1364-1374. doi: 10.1080/10428194.2017.1376743. Epub 2017 Sep 22.

PMID:
28937327
39.

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P.

Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23. Erratum in: Lancet Oncol. 2017 Oct;18(10):e562.

PMID:
28843768
40.

Recent advances in acute promyelocytic leukaemia.

Ng CH, Chng WJ.

F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017. Review.

41.

Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.

Zhou J, Bi C, Ching YQ, Chooi JY, Lu X, Quah JY, Toh SH, Chan ZL, Tan TZ, Chong PS, Chng WJ.

J Hematol Oncol. 2017 Jul 11;10(1):138. doi: 10.1186/s13045-017-0507-y.

42.

Identifying large indels in targeted next generation sequencing assays for myeloid neoplasms: a cautionary tale of the ZRSR1 pseudogene.

Ng IK, Ng C, Low JJ, Chiu L, Seah E, Ng CH, Chng WJ, Yan B, Ban KHK.

J Clin Pathol. 2017 Dec;70(12):1069-1073. doi: 10.1136/jclinpath-2017-204440. Epub 2017 Jul 4.

PMID:
28676493
43.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
44.

Super-Enhancers and Broad H3K4me3 Domains Form Complex Gene Regulatory Circuits Involving Chromatin Interactions.

Cao F, Fang Y, Tan HK, Goh Y, Choy JYH, Koh BTH, Hao Tan J, Bertin N, Ramadass A, Hunter E, Green J, Salter M, Akoulitchev A, Wang W, Chng WJ, Tenen DG, Fullwood MJ.

Sci Rep. 2017 May 19;7(1):2186. doi: 10.1038/s41598-017-02257-3.

45.

Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore.

Abid MB, Christopher D, Abid MA, Poon ML, Tan LK, Koh LP, Chng WJ.

Bone Marrow Transplant. 2017 Jul;52(7):1044-1046. doi: 10.1038/bmt.2017.77. Epub 2017 May 8. No abstract available.

PMID:
28481354
46.

Single-cell genomic profiling of acute myeloid leukemia for clinical use: A pilot study.

Yan B, Hu Y, Ban KHK, Tiang Z, Ng C, Lee J, Tan W, Chiu L, Tan TW, Seah E, Ng CH, Chng WJ, Foo R.

Oncol Lett. 2017 Mar;13(3):1625-1630. doi: 10.3892/ol.2017.5669. Epub 2017 Feb 1.

47.

The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations.

de Mel S, Li JB, Abid MB, Tang T, Tay HM, Ting WC, Poon LM, Chung TH, Mow B, Tso A, Ong KH, Chng WJ, Liu TC.

Cytometry B Clin Cytom. 2018 Jan;94(1):159-168. doi: 10.1002/cyto.b.21529. Epub 2017 May 4.

PMID:
28431200
48.

Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma.

Kong LR, Tan TZ, Ong WR, Bi C, Huynh H, Lee SC, Chng WJ, Eichhorn PJA, Goh BC.

Mol Oncol. 2017 Aug;11(8):965-980. doi: 10.1002/1878-0261.12064. Epub 2017 May 30.

49.

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E.

Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Review.

PMID:
28368259
50.

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Ludwig H, Dimopoulos MA, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D.

Leuk Lymphoma. 2017 Oct;58(10):2501-2504. doi: 10.1080/10428194.2017.1298755. Epub 2017 Mar 17. No abstract available.

PMID:
28306371

Supplemental Content

Support Center